Skip to main content

news

 

AZB & Partners has served as legal advisor to Mankind Pharma on its agreement to acquire Bharat Serums and Vaccines (BSV) for 136.3 billion rupees ($1.6 billion) from private equity firm Advent International, which has been guided by Khaitan & Co.

The deal will give Mankind, the maker of Manforce condoms and one of India's largest pharmaceutical companies, access to Bharat Serums' products targeting women's health and fertility treatments.

"This strategic move marks a significant leap for Mankind Pharma, positioning it as a market leader in the Indian women's health and fertility drug market alongside access to other high entry barrier products in critical care with established complex R&D tech platforms," Mankind said in a statement.

In securing this deal, Mankind outbid Swedish private equity firm EQT and the Abu Dhabi Investment Authority (ADIA) consortium, according to various reports.\

The AZB team representing Mankind comprised senior partner Vaidhyanadhan Iyer, partner Sneha Nagvekar, senior associates Sana Nagar and Karun Jhangiani, and associates Shivam Gupta and Akanksha Khandelwal. 

They were supported by finance partner Nikunj Maheshwari and antitrust partner Bharat Budholia. 

Khaitan’s team advising Advent and BSV included partners Aakash Choubey, Aashutosh Sampat, Sameer Sah, Anshuman Mozumdar; senior associates Ayush Sinha and Sagarika Chandel; and associates Aditi Halder, Ankush Unni, Amogh Pareek, Abhishek Singh, and Arun Kumar.

The acquisition is expected to close in the next three to four months, following which BSV will become a wholly owned unit of Mankind.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

7 international, Indian firms act on Kedaara Capital’s $350 mln U.S. bet

by Nimitt Dixit |

Akin Gump Strauss Hauer & Feld, Quillon Partners, and Kelley Drye & Warren have advised Indian private equity firm Kedaara Capital on its maiden bet in the data analytics and AI solutions market, committing $350 million strategic investment to San Jose, California-based Impetus Technologies.

Saraf, TT&A facilitate Fortis’ $207 mln buyout of PE investors in Agilus Diagnostics

by Nimitt Dixit |

Saraf and Partners has acted for Fortis Healthcare in relation to the $207 million acquisition of a 31.5 percent equity stake in its subsidiary, Agilus Diagnostics, from three private equity investors.

Trilegal, CAM act on Edelweiss’ $272 mln road projects acquisition

by Nimitt Dixit |

Trilegal has advised Edelweiss-backed Epic Concesiones 2 on its $272 million acquisition of 11 road projects from Ashoka Buildcon and Ashoka Concessions, which were represented by Cyril Amarchand Mangaldas.